Fujun Hou

Fujun Hou

Auto-generated profile, based on publicly available information

Fujun Hou

Virogin Biotech (Shanghai) Ltd (Virogin)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in RAIRO - Operations Research
Verified
Journal Article
Closed access
PDF file
ZLZhenkai Lou
Zhenkai Lou
XLXuming Lou
Xuming Lou
FHFujun Hou
Fujun Hou
This paper considers a two-level supply chain involving a supplier and a retailer. The retailer sells perishable products to consumers over a finite time horizon, and the demand is driven by a price-and-utility function. First, we study the noncooperative problem, which is formulated by a Stackelberg model. It is shown that the optimal pricing strategy of the retailer is to reduce a constant amount on the price at the beginning of each stage. Second, we examine the cooperative problem, in which the supplier and the retailer jointly price the product. Maximum selling cycle lengths of the two situations are obtained by analyzing the reasonability of the sales price. We demonstrate that the selling cycle length is extended by cooperation. Moreover, we show that they lower the sales price in the cooperative case so as to maximize the total profit. Meanwhile, an allocation method is provided based on the proportion.

5 October 2020 in Journal of Systems Science and Systems Engineering
Verified
Journal Article
Closed access
PDF file
ZLZhenkai Lou
Zhenkai Lou
FHFujun Hou
Fujun Hou
XLXuming Lou
Xuming Lou

6 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CLChangrui Lu
Changrui Lu
YZYuntao Zhang
Yuntao Zhang
XLXiaohu Liu
Xiaohu Liu
FHFujun Hou
Fujun Hou
RCRujie Cai
Rujie Cai
Xiaoming YangXiaoming Yang
Xiaoming Yang
The coronavirus SARS-CoV-2 has mutated quickly and caused significant global damage. This study characterizes two mRNA vaccines ZSVG-02 (Delta) and ZSVG-02-O (Omicron BA.1), and associating heterologous prime-boost strategy following the prime of a most widely administrated inactivated whole-virus vaccine (BBIBP-CorV). The ZSVG-02-O induces neutralizing antibodies that effectively cross-react with Omicron subvariants following an order of BA.1>BA.2>BA.4/5. In naïve animals, ZSVG-02 or ZSVG-02-O induce humoral responses skewed to the vaccine’s targeting strains, but cellular immune responses cross-react to all variants of concern (VOCs) tested. Following heterologous prime-boost regimes, animals present comparable neutralizing antibody levels and superior protection across all VOCs. Single-boost only generated ancestral and omicron dual-responsive antibodies, probably by “recall” and “reshape” the prime immunity. New Omicron-specific antibody populations, however, appeared only following the second boost with ZSVG-02-O. Overall, our results support a heterologous boost with ZSVG-02-O, providing the best protection against current VOCs in inactivated virus vaccine– primed populations.